医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Longhorn Vaccines & Diagnostics to Present at The 50th Union World Conference on Lung Health

2019年10月23日 PM11:00
このエントリーをはてなブックマークに追加


 

BETHESDA, Md.

Longhorn Vaccines & Diagnostics an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, will be participating and presenting scientific data at The 50th Union World Conference on Lung Health on October 30 – November 2 in Hyderabad, India. The conference is the largest gathering of clinicians and public health workers, health program managers, policymakers, researchers and advocates working to end the suffering caused by lung disease with a focus specifically on the challenges faced by low-and lower-middle income populations.

Longhorn Vaccines and Diagnostics executive team will lead the following oral abstract session:

Title: Targeted Next-Generation Sequencing Methodology for Characterizing High-Prevalence Multi-Drug Resistance Mycobacterium tuberculosis Mutations
Speaker: Luke T. Daum, Ph.D., Chief Scientific Officer, Longhorn Vaccines & Diagnostics
Date & Time: Friday, November 1 at 10:30 am IST
Location: MR 1.03 & 1.04

About Longhorn Vaccines and Diagnostics

Longhorn Vaccines & Diagnostics is an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations. Longhorn’s core product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA approved, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations and drug manufacturers improve the diagnosis and treatment of infectious diseases such as mycobacterium tuberculosis (TB) and Influenza. Unlike standard devices for collecting and transporting TB samples, MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization. Longhorn is based in Bethesda, Maryland.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191023005255/en/

CONTACT

Media:

Sean Leous

Westwicke/ICR PR

Phone: +1.646.677.1839

sean.leous@icrinc.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 複合細胞療法による尿道狭窄治療で特許を取得
  • Taiwan’s COVID-19 response win applause, friendship from around the world
  • EUSA Pharma宣布FDA核准Silvoximab治疗COVID-19相关急性呼吸窘迫综合征住院患者的3期临床试验
  • 治疗尿道狭窄的混合细胞疗法获得日本专利
  • 有力保健機関がハンドドライヤーの使用を推奨